Abstract:Abstract Background Multiple sclerosis (MS) is one of the most common autoimmune disorders characterized by the infiltration of immune cells into the brain and demyelination. The unwanted immunosuppressive side effect of therapeutically successful natalizumab led us to focus on the choroid plexus (CP), a key site for the first wave of immune cell infiltration in experimental autoimmune encephalomyelitis (EAE), for the control of immune cells trafficking. Adenosine A 2A receptor (A 2A R) is emerging as a potential pharmacological target to control EAE pathogenesis. However, the cellular basis for the A 2A R-mediated protection remains undetermined. Methods In the EAE model, we assessed A 2A R expression and leukocyte trafficking determinants in the CP by immunohistochemistry and qPCR analyses. We determined the effect of the A 2A R antagonist KW6002 treatment at days 8–12 or 8–14 post-immunization on T cell infiltration across the CP and EAE pathology. We determined the critical role of the CP-A 2A R on T cell infiltration and EAE pathology by focal knock-down of CP-A 2A R via intracerebroventricular injection of CRE-TAT recombinase into the A 2A R flox/flox mice. In the cultured CP epithelium, we also evaluated the effect of overexpression of A 2A Rs or the A 2A R agonist CGS21680 treatment on the CP permeability and lymphocytes migration. Results We found the specific upregulation of A 2A R in the CP associated with enhanced CP gateway activity peaked at day 12 post-immunization in EAE mice. Furthermore, the KW6002 treatment at days 8–12 or 8–14 post-immunization reduced T cell trafficking across the CP and attenuated EAE pathology. Importantly, focal CP-A 2A R knock-down attenuated the pathogenic infiltration of Th17 + cells across the CP via inhibiting the CCR6–CCL20 axis through NFκB/STAT3 pathway and protected against EAE pathology. Lastly, activation of A 2A R in the cultured epithelium by A 2A R overexpression or CGS21680 treatment increased the permeability of the CP epithelium and facilitated lymphocytes migration. Conclusion These findings define the CP niche as one of the primary sites of A 2A R action, whereby A 2A R antagonists confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A 2A R represents a novel therapeutic strategy for MS by controlling immune cell trafficking across CP.

Selective Inhibition of CCR7− Effector Memory T Cell Activation by a Novel Peptide Targeting Kv1.3 Channel in a Rat Experimental Autoimmune Encephalomyelitis Model

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

Kv1.3 channel blocker (ImKTx88) maintains blood–brain barrier in experimental autoimmune encephalomyelitis

Manipulation of Qa‐1‐restricted CD8 Suppressor Cell Activity in Experimental Autoimmune Encephalomyelitis

Radix Rehmanniae Extract Ameliorates Experimental Autoimmune Encephalomyelitis by Suppressing Macrophage-Derived Nitrative Damage

Dose-dependent anti-inflammatory and neuroprotective effects of an α β 3 integrin-binding peptide

CCDC134 Ameliorated Experimental Autoimmune Encephalomyelitis by Suppressing Th1 and Th17 Cells

Immunoregulation of Experimental Autoimmune Encephalomyelitis by the Selective CB1 Receptor Antagonist.

Structural Basis of a Potent Peptide Inhibitor Designed for Kv1.3 Channel, a Therapeutic Target of Autoimmune Disease

Regulatory Dendritic Cells Induced by K313 Display Anti-Inflammatory Properties and Ameliorate Experimental Autoimmune Encephalitis in Mice

Blockade of Kv1.3 potassium channel inhibits CD8+ T cell-mediated neuroinflammation via PD-1/Blimp-1 signaling

Choroid plexus-selective inactivation of adenosine A2A receptors protects against T cell infiltration and experimental autoimmune encephalomyelitis

Neuroprotective effects of a novel peptide through the Rho-integrin-Tie2 and PI3K/Akt pathways in experimental autoimmune encephalomyelitis model

High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis

Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis

Targeting CB2 receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis

The novel small molecule TPN10518 alleviates EAE pathogenesis by inhibiting AP1 to depress Th1/Th17 cell differentiation

Role of C16, angiopoietin-1 and regeneration gene protein 2 in attenuating inflammation in an experimental rat model of autoimmune encephalomyelitis.